Tevogen Bio Holdings Inc. (TVGN) Research

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.

Market snapshot

Symbol
TVGN
Price
$9.46
Day change
-2.47%
Market cap
$39.9M
P/E ratio
-1.54x
52-week range
4.135-71
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Atossa Therapeutics, Inc. (ATOS)
  • Cognition Therapeutics, Inc. (CGTX)
  • Clene Inc. (CLNN)
  • Greenwich LifeSciences, Inc. (GLSI)
  • TuHURA Biosciences, Inc. (HURA)
  • MacroGenics, Inc. (MGNX)
  • Oncolytics Biotech Inc. (ONCY)
  • Surrozen, Inc. (SRZN)

Recent insider activity

  • Flomenberg Neal — S-Sale (19 shares) on 2026-03-10
  • Flomenberg Neal — S-Sale (452 shares) on 2026-03-11
  • Flomenberg Neal — S-Sale (501 shares) on 2026-03-13
  • Saadi Ryan H. — G-Gift (50000 shares) on 2025-12-18
  • Desai Kirti — G-Gift (300000 shares) on 2025-12-11

Open Tevogen Bio Holdings Inc. (TVGN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.